Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia
Authors:
- 22 May 2008
- journal article
- Published by Springer Nature in Leukemia
- Vol. 22 (8) , 1542-1550
Abstract
Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well as unspecific immune reactions known as graft-versus-leukaemia (GvL) effects. Specific immune reactions are likely to be particularly relevant to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), in which residual cells may remain quiescent and unresponsive to cytotoxic and molecular therapies for long periods of time. Specific GvL effects result from the expression on leukaemic cells of specific tumour-associated antigens (TAAs) in the context of HLA proteins. As human leukocyte antigen (HLA) types vary widely, the development of broadly applicable tumour vaccines will require the identification of multiple TAAs active in different HLA backgrounds. Here, we describe the identification of NM23-H2 as a novel HLA-A32-restricted TAA of CML cells and demonstrate the presence of specifically reactive T cells in a patient 5 years after transplantation. As the NM23 proteins are aberrantly expressed in a range of different tumours, our findings suggest potential applications beyond CML and provide a new avenue of investigation into the molecular mechanisms underlying CML.Keywords
This publication has 46 references indexed in Scilit:
- The immunogenicity of Bcr-Abl–expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl–regulated antigensBlood, 2007
- BCR-ABL Activity Is Critical for the Immunogenicity of Chronic Myelogenous Leukemia CellsCancer Research, 2007
- Translational Mini-Review Series on Vaccines:
Peptide vaccines for myeloid leukaemiasClinical and Experimental Immunology, 2007
- Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell SurfaceMolecular & Cellular Proteomics, 2007
- Treatment of chronic myeloid leukemia with imatinib mesylateInternational Journal of Clinical Oncology, 2006
- Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemiaLeukemia, 2005
- Pediatric neuroblastomas: genetic and epigenetic ‘Danse Macabre’Gene, 2004
- The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2Oncogene, 2002
- Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodiesTissue Antigens, 1983
- Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysisCell, 1978